NTLA
Intellia Therapeutics, Inc.
Price Chart
Latest Quote
$15.25
-0.50 (-3.17%)
Current Price
| Previous Close | $15.75 |
| Open | $15.33 |
| Day High | $15.93 |
| Day Low | $15.06 |
| Volume | 4,781,393 |
Stock Information
| Shares Outstanding | 139.72M |
| Total Debt | $80.49M |
| Cash Equivalents | $375.99M |
| Revenue | $66.09M |
| Net Income | $-394.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.13B |
| EPS (TTM) | $-3.52 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.91B |
| Sales | $66.09M |
| Income | $-394.60M |
| Book/sh | $5.16 |
| Cash/sh | $2.69 |
| Employees | 377 |
Financial Ratios
| Quick Ratio | 5.04 |
| Current Ratio | 6.10 |
| Debt/Eq | 12.96 |
Returns & Margins
| ROA | -30.14% |
| ROE | -56.34% |
| Operating Margin | -668.07% |
Ownership
| Insider Ownership | 3.88% |
| Institutional Ownership | 76.72% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.47 |
| P/S | 32.24 |
| P/B | 2.96 |
Analyst Data
| Recommendation | buy |
| Target Price | $26.63 |
Technical Indicators
| SMA20 | $13.82 |
| SMA50 | $13.83 |
| SMA200 | $13.51 |
| RSI | 60.97 |
| ATR | 1.3882 |
| Shares Float | 134.16M |
| Short Float | 43.78% |
| Short Ratio | 6.54 |
| Volatility | 1.81 |
| Rel Volume | 0.71 |
Performance History
| Week | +2.21% |
| Month | +23.28% |
| Quarter | +16.32% |
| 6 Months | +71.73% |
| YTD | +65.58% |
| Year | +65.76% |
| 3 Years | -66.54% |
| 5 Years | -82.80% |
| 10 Years | -41.73% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $15.25 | 4,781,393 |
| 2026-06-22 | $15.75 | 5,103,700 |
| 2026-06-18 | $15.67 | 8,849,200 |
| 2026-06-17 | $15.20 | 12,427,200 |
| 2026-06-16 | $14.55 | 8,657,700 |
| 2026-06-15 | $14.92 | 16,409,500 |
| 2026-06-12 | $12.11 | 10,216,600 |
| 2026-06-11 | $12.35 | 7,935,800 |
| 2026-06-10 | $12.20 | 3,961,300 |
| 2026-06-09 | $12.89 | 5,627,600 |
| 2026-06-08 | $13.49 | 3,420,300 |
| 2026-06-05 | $13.54 | 7,484,300 |
| 2026-06-04 | $14.75 | 9,609,100 |
| 2026-06-03 | $13.02 | 3,101,400 |
| 2026-06-02 | $13.13 | 3,945,300 |
| 2026-06-01 | $13.73 | 3,569,500 |
| 2026-05-29 | $14.07 | 5,533,900 |
| 2026-05-28 | $13.68 | 4,525,500 |
| 2026-05-27 | $13.44 | 6,545,100 |
| 2026-05-26 | $12.61 | 3,618,900 |
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (ÂCRISPRÂ)/CRISPR associated 9 (ÂCas9Â) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-20T15:22:04Z
This Stock Is Up 58% This Year. Is It too Late to Buy?
Motley Fool âĸ 2026-06-17T06:50:00Z
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Zacks âĸ 2026-06-16T14:17:00Z
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Zacks âĸ 2026-06-16T12:43:00Z
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results
Insider Monkey âĸ 2026-06-16T02:46:04Z
Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?
Investor's Business Daily âĸ 2026-06-15T21:10:35Z
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Benzinga âĸ 2026-06-15T13:39:58Z
Exploring 3 High Growth Tech Stocks in US Market
Simply Wall St. âĸ 2026-06-15T11:39:04Z
Why Is NTLA Stock Jumping 5% Premarket Today?
Stocktwits âĸ 2026-06-15T08:10:26Z
Exploring High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-06-11T11:38:33Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $67,671,000 | $57,877,000 | $36,275,000 | $52,121,000 |
| Operating Revenue | $67,671,000 | $57,877,000 | $36,275,000 | $52,121,000 |
| Expenses | ||||
| Total Expenses | $508,661,000 | $592,140,000 | $551,566,000 | $510,285,000 |
| Other Income Expense | $-899,000 | $-32,565,000 | $-15,733,000 | $-24,564,000 |
| Net Non Operating Interest Income Expense | $29,195,000 | $47,807,000 | $49,832,000 | $8,542,000 |
| Operating Expense | $508,661,000 | $592,140,000 | $551,566,000 | $510,285,000 |
| General And Administrative Expense | $119,800,000 | $125,829,000 | $116,497,000 | $90,306,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Net Interest Income | $29,195,000 | $47,807,000 | $49,832,000 | $8,542,000 |
| Interest Income | $29,195,000 | $47,807,000 | $49,832,000 | $8,542,000 |
| Normalized Income | $-411,795,000 | $-486,456,000 | $-481,092,000 | $-460,701,000 |
| Net Income From Continuing And Discontinued Operation | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Total Operating Income As Reported | $-440,990,000 | $-534,263,000 | $-515,291,000 | $-458,164,000 |
| Net Income Common Stockholders | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Net Income | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Net Income Including Noncontrolling Interests | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Net Income Continuous Operations | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Pretax Income | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Special Income Charges | $0 | $0 | $-100,000 | $-13,485,000 |
| Earnings From Equity Interest | $0 | $0 | $-15,633,000 | $-11,079,000 |
| Interest Income Non Operating | $29,195,000 | $47,807,000 | $49,832,000 | $8,542,000 |
| Operating Income | $-440,990,000 | $-534,263,000 | $-515,291,000 | $-458,164,000 |
| Per Share | ||||
| Diluted EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 |
| Basic EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-424,168,000 | $-491,413,000 | $-506,215,000 | $-437,107,000 |
| Total Unusual Items | $-899,000 | $-32,565,000 | $-100,000 | $-13,485,000 |
| Total Unusual Items Excluding Goodwill | $-899,000 | $-32,565,000 | $-100,000 | $-13,485,000 |
| Reconciled Depreciation | $15,923,000 | $10,285,000 | $8,976,000 | $7,572,000 |
| EBITDA (Bullshit earnings) | $-425,067,000 | $-523,978,000 | $-506,315,000 | $-450,592,000 |
| EBIT | $-440,990,000 | $-534,263,000 | $-515,291,000 | $-458,164,000 |
| Diluted Average Shares | $108,376,000 | $98,849,000 | $88,770,000 | $76,972,000 |
| Basic Average Shares | $108,376,000 | $98,849,000 | $88,770,000 | $76,972,000 |
| Diluted NI Availto Com Stockholders | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Restructuring And Mergern Acquisition | $0 | $0 | $100,000 | $13,485,000 |
| Gain On Sale Of Security | $-899,000 | $-32,565,000 | - | - |
| Research And Development | $388,861,000 | $466,311,000 | $435,069,000 | $419,979,000 |
| Selling General And Administration | $119,800,000 | $125,829,000 | $116,497,000 | $90,306,000 |
| Other Gand A | $119,800,000 | $125,829,000 | $116,497,000 | $90,306,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Total Assets | $842,127,000 | $1,191,015,000 | $1,300,977,000 | $1,520,114,000 |
| Total Non Current Assets | $314,416,000 | $551,152,000 | $302,647,000 | $303,317,000 |
| Investmentin Financial Assets | $155,250,000 | $260,215,000 | $99,864,000 | $69,338,000 |
| Current Assets | $527,711,000 | $639,863,000 | $998,330,000 | $1,216,797,000 |
| Other Current Assets | $68,359,000 | $29,831,000 | $49,651,000 | $20,407,000 |
| Receivables | $9,468,000 | $8,517,000 | $36,456,000 | $3,768,000 |
| Accounts Receivable | $9,468,000 | $8,517,000 | $36,456,000 | $3,768,000 |
| Cash Cash Equivalents And Short Term Investments | $449,884,000 | $601,515,000 | $912,223,000 | $1,192,622,000 |
| Cash And Cash Equivalents | $155,464,000 | $189,182,000 | $226,748,000 | $523,506,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $93,329,000 | $210,198,000 | $115,346,000 | $130,703,000 |
| Long Term Debt And Capital Lease Obligation | $66,849,000 | $189,952,000 | $96,747,000 | $114,018,000 |
| Current Debt And Capital Lease Obligation | $26,480,000 | $20,246,000 | $18,599,000 | $16,685,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $170,733,000 | $319,059,000 | $250,808,000 | $284,530,000 |
| Total Non Current Liabilities Net Minority Interest | $66,849,000 | $208,208,000 | $135,600,000 | $157,976,000 |
| Non Current Deferred Liabilities | $0 | $18,256,000 | $38,853,000 | $19,932,000 |
| Current Liabilities | $103,884,000 | $110,851,000 | $115,208,000 | $126,554,000 |
| Current Deferred Liabilities | $7,290,000 | $20,661,000 | $22,140,000 | $43,839,000 |
| Payables And Accrued Expenses | $47,042,000 | $45,869,000 | $47,854,000 | $44,252,000 |
| Payables | $20,252,000 | $14,589,000 | $7,452,000 | $5,154,000 |
| Accounts Payable | $20,252,000 | $14,589,000 | $7,452,000 | $5,154,000 |
| Other Non Current Liabilities | - | - | - | $24,026,000 |
| Equity | ||||
| Common Stock Equity | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Total Equity Gross Minority Interest | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Stockholders Equity | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Gains Losses Not Affecting Retained Earnings | $1,032,000 | $605,000 | $-2,258,000 | $-7,461,000 |
| Other Equity Adjustments | $1,032,000 | $605,000 | $-2,258,000 | $-7,461,000 |
| Retained Earnings | $-2,590,094,000 | $-2,177,400,000 | $-1,658,379,000 | $-1,177,187,000 |
| Long Term Equity Investment | - | $0 | $11,765,000 | $32,455,000 |
| Other | ||||
| Ordinary Shares Number | $116,317,060 | $102,029,594 | $92,997,158 | $87,103,007 |
| Share Issued | $116,317,060 | $102,029,594 | $92,997,158 | $87,103,007 |
| Tangible Book Value | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Invested Capital | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Working Capital | $423,827,000 | $529,012,000 | $883,122,000 | $1,090,243,000 |
| Capital Lease Obligations | $93,329,000 | $210,198,000 | $115,346,000 | $130,703,000 |
| Total Capitalization | $671,394,000 | $871,956,000 | $1,050,169,000 | $1,235,584,000 |
| Additional Paid In Capital | $3,260,444,000 | $3,048,741,000 | $2,710,797,000 | $2,420,223,000 |
| Capital Stock | $12,000 | $10,000 | $9,000 | $9,000 |
| Common Stock | $12,000 | $10,000 | $9,000 | $9,000 |
| Non Current Deferred Revenue | $0 | $18,256,000 | $38,853,000 | $19,932,000 |
| Long Term Capital Lease Obligation | $66,849,000 | $189,952,000 | $96,747,000 | $114,018,000 |
| Current Deferred Revenue | $7,290,000 | $20,661,000 | $22,140,000 | $43,839,000 |
| Current Capital Lease Obligation | $26,480,000 | $20,246,000 | $18,599,000 | $16,685,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $23,072,000 | $24,075,000 | $26,615,000 | $21,778,000 |
| Current Accrued Expenses | $26,790,000 | $31,280,000 | $40,402,000 | $39,098,000 |
| Investments And Advances | $190,790,000 | $304,479,000 | $154,512,000 | $142,320,000 |
| Other Investments | $35,540,000 | $44,264,000 | $42,883,000 | $40,527,000 |
| Available For Sale Securities | $155,250,000 | $260,215,000 | $99,864,000 | $69,338,000 |
| Net PPE | $123,626,000 | $246,673,000 | $148,135,000 | $160,997,000 |
| Accumulated Depreciation | $-58,606,000 | $-49,691,000 | $-39,861,000 | $-33,199,000 |
| Gross PPE | $182,232,000 | $296,364,000 | $187,996,000 | $194,196,000 |
| Leases | $3,199,000 | $3,199,000 | $3,134,000 | $3,066,000 |
| Other Properties | $173,824,000 | $287,646,000 | $179,345,000 | $184,987,000 |
| Machinery Furniture Equipment | $5,209,000 | $5,519,000 | $5,517,000 | $6,143,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $294,420,000 | $412,333,000 | $685,475,000 | $669,116,000 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-395,865,000 | $-354,658,000 | $-408,071,000 | $-391,677,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-394,736,000 | $-348,880,000 | $-394,086,000 | $-333,287,000 |
| Cash Flow From Continuing Operating Activities | $-394,736,000 | $-348,880,000 | $-394,086,000 | $-333,287,000 |
| Operating Gains Losses | $527,000 | $-76,000 | $15,705,000 | $10,917,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,129,000 | $-5,778,000 | $-13,985,000 | $-58,390,000 |
| Investing Cash Flow | $228,031,000 | $125,567,000 | $-31,347,000 | $160,309,000 |
| Cash Flow From Continuing Investing Activities | $228,031,000 | $125,567,000 | $-31,347,000 | $160,309,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $128,175,000 | $176,899,000 | $119,795,000 | $565,789,000 |
| Financing Cash Flow | $131,486,000 | $185,747,000 | $130,323,000 | $582,955,000 |
| Cash Flow From Continuing Financing Activities | $131,486,000 | $185,747,000 | $130,323,000 | $582,955,000 |
| Net Common Stock Issuance | $128,175,000 | $176,899,000 | $119,795,000 | $565,789,000 |
| Common Stock Issuance | $128,175,000 | $176,899,000 | $119,795,000 | $565,789,000 |
| Other | ||||
| End Cash Position | $167,568,000 | $202,787,000 | $240,353,000 | $535,463,000 |
| Beginning Cash Position | $202,787,000 | $240,353,000 | $535,463,000 | $125,486,000 |
| Changes In Cash | $-35,219,000 | $-37,566,000 | $-295,110,000 | $409,977,000 |
| Proceeds From Stock Option Exercised | $3,311,000 | $8,848,000 | $10,528,000 | $17,166,000 |
| Net Investment Purchase And Sale | $229,160,000 | $131,345,000 | $-17,362,000 | $218,549,000 |
| Sale Of Investment | $551,670,000 | $1,066,918,000 | $887,102,000 | $647,581,000 |
| Purchase Of Investment | $-322,510,000 | $-935,573,000 | $-904,464,000 | $-429,032,000 |
| Net PPE Purchase And Sale | $-1,129,000 | $-5,778,000 | $-13,985,000 | $-13,408,000 |
| Purchase Of PPE | $-1,129,000 | $-5,778,000 | $-13,985,000 | $-13,558,000 |
| Change In Working Capital | $-73,752,000 | $11,878,000 | $-52,452,000 | $-53,873,000 |
| Change In Other Working Capital | $-28,111,000 | $-22,076,000 | $-2,778,000 | $-63,464,000 |
| Change In Other Current Liabilities | $-54,951,000 | $-17,969,000 | $-16,668,000 | $-9,882,000 |
| Change In Other Current Assets | $35,897,000 | $22,383,000 | $18,304,000 | $12,030,000 |
| Change In Payables And Accrued Expense | $716,000 | $-3,583,000 | $8,546,000 | $11,340,000 |
| Change In Accrued Expense | $-5,271,000 | $-10,383,000 | $6,024,000 | $15,924,000 |
| Change In Payable | $5,987,000 | $6,800,000 | $2,522,000 | $-4,584,000 |
| Change In Account Payable | $5,987,000 | $6,800,000 | $2,522,000 | $-4,584,000 |
| Change In Prepaid Assets | $-26,352,000 | $5,184,000 | $-27,168,000 | $-2,160,000 |
| Change In Receivables | $-951,000 | $27,939,000 | $-32,688,000 | $-1,737,000 |
| Changes In Account Receivables | $-951,000 | $27,939,000 | $-32,688,000 | $-1,737,000 |
| Stock Based Compensation | $80,219,000 | $154,273,000 | $134,050,000 | $91,400,000 |
| Unrealized Gain Loss On Investment Securities | $899,000 | $32,565,000 | $0 | $0 |
| Amortization Of Securities | $-5,858,000 | $-17,817,000 | $-25,897,000 | $4,003,000 |
| Depreciation Amortization Depletion | $15,923,000 | $10,285,000 | $8,976,000 | $7,572,000 |
| Depreciation And Amortization | $15,923,000 | $10,285,000 | $8,976,000 | $7,572,000 |
| Depreciation | $15,923,000 | $10,285,000 | $8,976,000 | - |
| Earnings Losses From Equity Investments | $0 | $0 | $15,633,000 | $11,079,000 |
| Gain Loss On Sale Of PPE | $527,000 | $-76,000 | $72,000 | $-162,000 |
| Net Income From Continuing Operations | $-412,694,000 | $-519,021,000 | $-481,192,000 | $-474,186,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-44,832,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-44,832,000 |
| Sale Of PPE | - | $0 | $0 | $150,000 |
| Other Non Cash Items | - | $-20,967,000 | $6,724,000 | $80,880,000 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
Fetched: 2026-06-21